EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Vitamin D 3 Supplementation Along With Topiramate in Pediatric Migraine Prophylaxis: Is it Effective?

Prateek Kumar Panda iD, Aparna Ramachandran, Indar Kumar Sharawat iD

Journal of Child Neurology · 2023

DOI: 10.1177/08830738231155792 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Child Neurology, 2023. Verfasst von Prateek Kumar Panda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India. Hauptthemen laut MEDLINE: Cholecalciferol, Migraine Disorders. Die Arbeit nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We read with interest the recently published article titled “The Impact of Vitamin D3 Supplementation to Topiramate Therapy on Pediatric Migraine Prophylaxis” by Elmala et al. The authors have demonstrated that Vitamin D3 supplementation in pediatric migraine prophylaxis could be a well-tolerated, safe, and effective strategy. However, we wish to add certain points. The authors used a 5000-IU/d dose of oral vitamin D for 4 months, whereas in a trial with similar objectives and geographical region, Fallah et al used a dose of 500 000 IU vitamin D3 pearls weekly for 2 consecutive months. Gazerani et al and Buettner et al on the other hand used an oral vitamin D dose of 2000 IU/d. Recommendations by the Indian Academy of Pediatrics suggest a daily oral vitamin D dosing schedule of 2000 IU below 1 year of age and 3000 IU in older children for 12 weeks. Hence, the authors need to mention the recommendations behind the dosing schedule they used in their study. Because vitamin D is a fat-soluble vitamin and the investigators have only enrolled patients with normal serum vitamin D levels, there is a risk of vitamin D toxicity on prolonged daily dosing. Although the authors have mentioned in the methodology that they have monitored serum vitamin D levels at baseline and after 4 months, they have not mentioned in the results how many participants have serum vitamin D levels in the range of toxicity and change in serum vitamin D level in the placebo group. The authors havementioned that all participants had equal exposure to direct sunlight, but they have not mentioned how they came to this conclusion and whether they have used any objective measures or questionnaires like Long Term (LT) and Short Term (ST) Sunlight Exposure Measurement Questionnaires (SEM-Q). Sunlight exposure is known to have an impact on serum vitamin D levels in human subjects. The authors need to recheck the P values mentioned for comparison of primary and secondary outcomes between the 2 groups. We estimated the P values for comparison of monthly headache frequency and disability from headaches between two groups to be 50% reduction in headache frequency to be 0.18 (chi-square test as used by investigators), instead of the .01 mentioned by the authors. This suggests the proportion of patients with >50% reduction in headache frequency was not significantly better in the additional vitamin D supplementation group. The median patient satisfaction score mentioned by the authors were 2 (dissatisfied) and 3 (somewhat dissatisfied) in both groups. It shows that the majority of patients were dissatisfied with the treatments prescribed and whether the difference in headache frequency between the 2 groups is really clinically meaningful needs to be addressed by the authors. The authors have not mentioned whether they have followed the intention-to-treat or per-protocol approach while analyzing for primary and secondary outcomes and how they filled up the missing data of 4 participants while analyzing. Moreover, they have also not mentioned how they measured the severity of headache attacks, whether they used the 11-point visual analog scale or any other scale. The authors did not mention using any headache diary by the parents; rather they used a parental recall-based questionnaire during the follow-up visits, which could have confounded the results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholecalciferolMigraine DisordersHumansChildTopiramateAnticonvulsantsDietary SupplementsFructose

Substanzen

TopiramateCholecalciferolAnticonvulsantsFructose

Autor:innen und Institutionen

  • Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
  • Department of Neurology, IQRAA International Hospital and Research Centre, Kozhikode, Kerala, India.

ORCID-Profile: Prateek Kumar Panda, Indar Kumar Sharawat

Zitieren

APA

Panda, P. K., Ramachandran, A., & Sharawat, I. K. (2023). Vitamin D 3 Supplementation Along With Topiramate in Pediatric Migraine Prophylaxis: Is it Effective?. Journal of Child Neurology. https://doi.org/10.1177/08830738231155792

Vancouver

Panda PK, Ramachandran A, Sharawat IK. Vitamin D 3 Supplementation Along With Topiramate in Pediatric Migraine Prophylaxis: Is it Effective?. Journal of Child Neurology. 2023. doi:10.1177/08830738231155792

BibTeX
@article{Panda2023,
  author = {Panda, Prateek Kumar and Ramachandran, Aparna and Sharawat, Indar Kumar},
  title = {Vitamin D 3 Supplementation Along With Topiramate in Pediatric Migraine Prophylaxis: Is it Effective?},
  journal = {Journal of Child Neurology},
  year = {2023},
  doi = {10.1177/08830738231155792}
}
Kostenlos starten →